Donanemab marks start of “new story” in Alzheimer’s research
Professor Craig Ritchie has told an international Alzheimer’s conference that phase 3 clinical trial results for donanemab, the antibody drug designed to target and clear the amyloid plaques considered key to progression of Alzheimer’s disease, reveal the drug’s “profound” clinical effect.